Neomics Pharmaceuticals

Executive Summary

Neomics Pharmaceuticals is a preclinical-stage French biotechnology company pioneering novel T cell-based immunotherapies for cancer and immune-mediated diseases. The company's core differentiator lies in its immunogenomics platform, which identifies disease-specific T-cell receptors (TCRs) and engineers them into a proprietary third-generation CAR (Chimeric Antigen Receptor) format. This approach aims to overcome key limitations of current cell therapies, such as antigen escape and poor persistence, by leveraging natural TCR signaling combined with enhanced co-stimulatory domains. Neomics' platform is designed to address both hematologic malignancies and solid tumors, an area where many CAR-T therapies have struggled. The company's lead programs are in preclinical development, focusing on targets with high unmet medical need. While still early-stage, Neomics represents a promising approach in the rapidly evolving cell therapy landscape, with potential to deliver more durable and effective treatments.

Upcoming Catalysts (preview)

• H2 2026Preclinical proof-of-concept data for lead TCR-CAR program60% success
• Q2 2026Series A financing completion to advance pipeline70% success
• Q1 2027IND-enabling studies initiation for lead candidate50% success